Pnd30 the Societal Impact of Erenumab in Prophylactic Treatment of Patients With Migraine in Germany: A Macroeconomic Open-Cohort Approach

Abstract

ICER is 262,30 V/week on NEDA. Conclusions: Although more expensive in terms of drug acquisition costs, Interferon beta-1a 44mcg tiw results in a lower cost-effectiveness ratio in terms of cost per week achieved on NEDA, thus dominating by extension Interferon beta-1a 30mcg qw and being a better option if value for money is the main focus.